Dr. Lance Feller, Rheumatologist
Dr. Lance Feller is a board-certified rheumatologist with dual fellowship training in adult and pediatric rheumatology. His research and clinical experience encompasses a variety of health conditions, including juvenile arthritis, lupus, and scleroderma. He has a special interest in caring for adults with pediatric rheumatology conditions and helping to transition adolescents with rheumatic diseases.
Prior to joining Central Florida Rheumatology Consultants, Dr. Feller was the Medical Director at Inland Rheumatology in Maine. He was previously an Assistant Professor at the University of Central Florida College of Medicine, where he trained rheumatology fellows and was Site Director for their fellowship program.
He is a Fellow of the American College of Rheumatology (FACR), a former member of the Childhood Arthritis and Rheumatology Research Alliance (CARRA), and a member of the National Med-Peds Residents’ Association (NMPRA).
Education
Dr. Feller earned his bachelor’s degree in biochemistry, cell biology, and psychology from the University of California, San Diego. He then received his medical degree from St. George’s University School of Medicine, followed by a dual residency in internal medicine and pediatrics at Newark Beth Israel Medical Center in New Jersey. He completed both adult and pediatric rheumatology fellowships at the Saint Louis University School of Medicine.
Research
1. Dalrymple A, Tuttle P, Feller L, Zhukov O, Lagier R, Popov J, Naides S, Moore TL. 14-3-3 eta Protein as a Potential Biomarker in Juvenile Idiopathic Arthritis. Pediatr. Rep. 2021, 13(1), 65-71; https://doi.org/10.3390/pediatric13010008
2. Moore T, Dalrymple A, Feller L, Tuttle P. Minor Biomarkers in Juvenile Idiopathic Arthritis (JIA) [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4).
https://acrabstracts.org/abstract/minor-biomarkers-in-juvenile-idiopathic-arthritis-jia/. Accessed November 18, 2020.
3. Chawla A, Vuyyuru S, Feller L. Favorably Unfavorable: Interstitial Lung Disease as the Initial Manifestation of Anti-Mi-2 Positive Dermatomyositis. Ann Arthritis Clin Rheumatol. 2020; 3(1): 1019.
4. Chawla A, Macias KC, Vuyyuru S, Gros B, Feller L. Elevated Alkaline Phosphatase: The initial laboratory abnormality in an atypical presentation of Takayasu arteritis. Int. J. Clin. Rheumatol. (2020) 15(2), 33-36.
5. Chawla A, Vuyyuru S, Feller L. Favorably Unfavorable: Interstitial Lung Disease as the Initial Manifestation of Anti-Mi-2 Positive Dermatomyositis [abstract]. (Presented Congress of Clinical Rheumatology, San Diego CA, September 2019).
6. Chawla A, Macias KC, Vuyyuru S, Gros B, Feller L. Elevated Alkaline Phosphatase: The Initial Laboratory Abnormality in an Atypical Presentation of Takayasu Arteritis [abstract]. (Presented Congress of Clinical Rheumatology, Destin FL, May 2019).
7. Spencer et al. Biologic Therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America. Pediatric Rheumatology (2017) 15:50. DOI 10.1186/s12969-017-0174-0.
8. Dalrymple AM, Tuttle P IV, Feller L, Zhukov OS, Lagier RJ, Bridgforth R, Williams GJ, Popov JM, Naides SJ, Moore T. 14-3-3η (eta) Protein in Juvenile Idiopathic Arthritis (JIA) Patients [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). (Presented ACR/ARHP Annual Scientific Meeting, San Diego, Nov 2017).
9. Dalrymple A, Tuttle P IV, Feller L, Zhukov OS, Lagier RJ, Bridgforth R, Williams GJ, Popov J, Naides SJ, Moore T. 14-3-3π(eta) Protein in Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 4). (Presented Pediatric Rheumatology Symposium (PRSYM), Houston, May 2017).
10. Feller L, Dalrymple AM, Tuttle P IV, Syed RH, Pepmueller P, Moore T. Examination of the Clinical Significance of 14-3-3 Eta in Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). (Presented ACR/ARHP Annual Scientific Meeting, San Francisco, Nov 2015).
11. Feller L, Tuttle P IV, Dalrymple AM, Bathula S, Temprano K, Syed RH, Bandlamudi R, Coulson K, Pepmueller P, Moore T. Single Academic Center Experience with 14-3-3 Eta in the Evaluation of Inflammatory Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). (Presented at ACR/ARHP Annual Scientific Meeting, San Francisco, Nov 2015).
12. Feller LS, Tuttle PV, Moore TL: Clinical utility of 14-3-3n in the evaluation of inflammatory arthritis. Arthritis Rheum 66:S170, 2014 (Presented American College of Rheumatology, Boston, MA, November 2014).
13. Feller L, Gilliam B, Cleland E, Syed RH, Pepmueller, PH, Moore TL: Demonstration of antibodies to multiple citrullinated epitopes in the sera of patients with juvenile idiopathic arthritis. Arthritis Rheum 66:S154, 2014 (Presented Pediatric Rheumatology Symposium, Orlando, FL, April 2014).
14. Moore TL, Gilliam BE, Crespo-Pagnussat S, Feller L, Chauhan AK: Measurement and evaluation of isotypes of anti-citrullinated fibrinogen and anti-citrullinated α-enolase antibodies in juvenile idiopathic arthritis. Clin Exp Rheumatol 32:740-746, 2014.
15. Gilliam B, Feller L, Moore TL: IgG anti-cyclic citrullinated peptide antibodies are associated with joint destruction in juvenile idiopathic arthritis patients. Arthritis Rheum 65:S937, 2013 (Presented American College of Rheumatology, San Diego, CA, October 2013).